Mane Arati, Sahasrabuddhe Vikrant V, Nirmalkar Amit, Risbud Arun R, Sahay Seema, Bhosale Ramesh A, Vermund Sten H, Mehendale Sanjay M
National AIDS Research Institute, Pune, India.
National Cancer Institute, Rockville, USA.
J Clin Virol. 2017 Mar;88:26-32. doi: 10.1016/j.jcv.2016.10.013. Epub 2016 Oct 28.
Several studies in recent years have documented the genotype-specific prevalence of HPV infection and wide diversity and multiplicity of HPV genotypes among HIV-seropositive women. Yet, information on changes in HPV genotype-specific incidence and clearance rates over time, and their correlation with clinical or immunologic factors among HIV-seropositive women is scarce.
We conducted a prospective study to investigate the incidence and clearance rates of cervical HPV genotypes among HIV-seropositive women in India and expand the evidence base in this area of research.
Cervical samples were collected from n=215 HIV-seropositive women in Pune, India who underwent two screening visits separated by a median of 11-months (interquartile range: 8-18 months). HPV genotypes were determined by Roche Linear Array HPV assay. Individual genotype-specific and carcinogenicity-grouping-specific HPV incidence and clearance rates were calculated and the associations between incidence/clearance and age and HIV-related metrics were explored.
Incidence and clearance rates for 'any HPV' and 'carcinogenic HPV' genotypes were 11.1 and 18.3, and 6.7 and 33.8, per 100 person-years, respectively. Incidence and clearance rates for HPV genotypes of alpha-9 species (HPV16, HPV31, HPV33, HPV35, HPV52 and HPV58) and alpha-7 species (HPV18, HPV39, HPV45, HPV59 and HPV68) were 5.8 and 2.04, and 32.1 and 53.5, per 100 person-years, respectively. Clearance of any HPV type was associated with increasing age of participants (odds ratio: 1.08, 95%CI: 1.004-1.17), although the association marginally lost its statistical significance when adjusted for CD4 counts and antiretroviral therapy status.
Genotype-specific clearance rates of HPV were higher than corresponding incidence rates. The suggestion of a positive associations of increasing age with HPV clearance points to the need for etiologic studies on age-related hormonal changes on clearance of cervical HPV infection.
近年来的多项研究记录了HIV血清阳性女性中HPV感染的基因型特异性患病率以及HPV基因型的广泛多样性和多重性。然而,关于HIV血清阳性女性中HPV基因型特异性发病率和清除率随时间的变化及其与临床或免疫因素的相关性的信息却很少。
我们进行了一项前瞻性研究,以调查印度HIV血清阳性女性中宫颈HPV基因型的发病率和清除率,并扩大该研究领域的证据基础。
从印度浦那的215名HIV血清阳性女性中收集宫颈样本,这些女性接受了两次筛查,中间间隔时间中位数为11个月(四分位间距:8 - 18个月)。通过罗氏线性阵列HPV检测法确定HPV基因型。计算个体基因型特异性和致癌性分组特异性的HPV发病率和清除率,并探讨发病率/清除率与年龄和HIV相关指标之间的关联。
“任何HPV”和“致癌性HPV”基因型的发病率和清除率分别为每100人年11.1和18.3,以及6.7和33.8。α-9物种(HPV16、HPV31、HPV33、HPV35、HPV52和HPV58)和α-7物种(HPV18、HPV39、HPV45、HPV59和HPV68)的HPV基因型发病率和清除率分别为每100人年5.8和2.04,以及32.1和53.5。任何HPV类型的清除与参与者年龄的增加相关(优势比:1.08,95%置信区间:1.004 - 1.17),尽管在调整CD4细胞计数和抗逆转录病毒治疗状态后,这种关联的统计学意义略有丧失。
HPV的基因型特异性清除率高于相应的发病率。年龄增加与HPV清除呈正相关的这一迹象表明,需要对与年龄相关的激素变化对宫颈HPV感染清除的影响进行病因学研究。